drugset / Trial / NCT01324505
Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes
Non-randomizedCrossoverOpen-labelTreatment
Summary
This clinical trial is conducted in Europe. The purpose of the trial is to investigate the influence on the pharmacokinetics (the rate at which the trial drug is eliminated from the body) of an oral contraceptive combination drug after multiple administration of semaglutide in female subjects with type 2 diabetes.
Timeline
- Start
- 2011-03
- Primary completion
- 2012-01
- Completion
- 2012-01
Publications
- Results Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analogue, does not reduce the bioavailability of oral contraceptives in patients with type 2 diabetes. Diabetes 2014; 63 (suppl 1): A595-A631 (2383-PO)
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Levonorgestrel | Small molecule | 0.15 mg | Oral |
| Subject | Semaglutide | Peptide | — | Subcutaneous |
| Subject | ethinyl estradiol | Small molecule | 0.03 mg | Oral |